Literature DB >> 23176506

Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis.

Petra Lukacik1, Travis J Barnard, Susan K Buchanan.   

Abstract

Purified phage lysins present an alternative to traditional antibiotics and work by hydrolysing peptidoglycan. Phage lysins have been developed against Gram-positive pathogens such as Bacillus anthracis and Streptococcus pneumoniae, where the peptidoglycan layer is exposed on the cell surface. Addition of the lysin to a bacterial culture results in rapid death of the organism. Gram-negative bacteria are resistant to phage lysins because they contain an outer membrane that protects the peptidoglycan from degradation. We solved crystal structures of a Yersinia pestis outer-membrane protein and the bacteriocin that targets it, which informed engineering of a bacterial-phage hybrid lysin that can be transported across the outer membrane to kill specific Gram-negative bacteria. This work provides a template for engineering phage lysins against a wide variety of bacterial pathogens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23176506      PMCID: PMC3679646          DOI: 10.1042/BST20120209

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  25 in total

1.  The three dimensional structure of the lysozyme from bacteriophage T4.

Authors:  B W Matthews; S J Remington
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

2.  Control of enzyme activity by an engineered disulfide bond.

Authors:  M Matsumura; B W Matthews
Journal:  Science       Date:  1989-02-10       Impact factor: 47.728

3.  Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase.

Authors:  J M Loeffler; D Nelson; V A Fischetti
Journal:  Science       Date:  2001-12-07       Impact factor: 47.728

4.  Accumulation of iron by yersiniae.

Authors:  R D Perry; R R Brubaker
Journal:  J Bacteriol       Date:  1979-03       Impact factor: 3.490

5.  Phylogenetic analysis and prevalence of urosepsis strains of Escherichia coli bearing pathogenicity island-like domains.

Authors:  Martine Bingen-Bidois; Olivier Clermont; Stéphane Bonacorsi; Mustapha Terki; Naïma Brahimi; Chawki Loukil; Dominique Barraud; Edouard Bingen
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

6.  Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise.

Authors:  J R Johnson; A L Stell
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

7.  Mode of action of pesticin: N-acetylglucosaminidase activity.

Authors:  D M Ferber; R R Brubaker
Journal:  J Bacteriol       Date:  1979-08       Impact factor: 3.490

8.  The pesticin receptor of Yersinia enterocolitica: a novel virulence factor with dual function.

Authors:  A Rakin; E Saken; D Harmsen; J Heesemann
Journal:  Mol Microbiol       Date:  1994-07       Impact factor: 3.501

9.  A bacteriolytic agent that detects and kills Bacillus anthracis.

Authors:  Raymond Schuch; Daniel Nelson; Vincent A Fischetti
Journal:  Nature       Date:  2002-08-22       Impact factor: 49.962

10.  Structural and mechanistic studies of pesticin, a bacterial homolog of phage lysozymes.

Authors:  Silke I Patzer; Reinhard Albrecht; Volkmar Braun; Kornelius Zeth
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

View more
  10 in total

Review 1.  Managing urinary tract infections through phage therapy: a novel approach.

Authors:  Shikha Malik; Parveen Kaur Sidhu; J S Rana; Kiran Nehra
Journal:  Folia Microbiol (Praha)       Date:  2019-09-07       Impact factor: 2.099

2.  Novel Engineered Peptides of a Phage Lysin as Effective Antimicrobials against Multidrug-Resistant Acinetobacter baumannii.

Authors:  Mya Thandar; Rolf Lood; Benjamin Y Winer; Douglas R Deutsch; Chad W Euler; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii.

Authors:  Valerie Defraine; Joris Schuermans; Barbara Grymonprez; Sander K Govers; Abram Aertsen; Maarten Fauvart; Jan Michiels; Rob Lavigne; Yves Briers
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 4.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23

Review 5.  Bacteriophages and Their Immunological Applications against Infectious Threats.

Authors:  Elena Criscuolo; Sara Spadini; Jacopo Lamanna; Mattia Ferro; Roberto Burioni
Journal:  J Immunol Res       Date:  2017-04-16       Impact factor: 4.818

6.  The therapeutic potential of bacteriocins as protein antibiotics.

Authors:  Hannah M Behrens; Anne Six; Daniel Walker; Colin Kleanthous
Journal:  Emerg Top Life Sci       Date:  2017-04-21

7.  P22 Phage Shows Promising Antibacterial Activity under Pathophysiological Conditions.

Authors:  Logan Gildea; Joseph A Ayariga; Boakai K Robertson; Robert Villafane
Journal:  Arch Microbiol Immunol       Date:  2022-02-10

Review 8.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12

9.  Antibacterial activity of a lectin-like Burkholderia cenocepacia protein.

Authors:  Maarten G K Ghequire; Evelien De Canck; Pierre Wattiau; Iris Van Winge; Remy Loris; Tom Coenye; René De Mot
Journal:  Microbiologyopen       Date:  2013-06-05       Impact factor: 3.139

Review 10.  Future Drug Targets in Periodontal Personalised Medicine-A Narrative Review.

Authors:  Pradeep Kumar Yadalam; V Kalaivani; Hammam Ibrahim Fageeh; Wael Ibraheem; Manea Musa Al-Ahmari; Samar Saeed Khan; Zeeshan Heera Ahmed; Hesham H Abdulkarim; Hosam Ali Baeshen; Thodur Madapusi Balaji; Shilpa Bhandi; A Thirumal Raj; Shankargouda Patil
Journal:  J Pers Med       Date:  2022-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.